Search

Trigeminal trophic syndrome is an uncommon condition characterized by paresthesia, itch, and self-inflicted wounds following the trigeminal dermatome(s). Similar processes adhering to cervical nerve distributions have been reported, calling into question the specificity of trigeminal trophic syndrome for the trigeminal network. Herein, we report patient with trigeminal trophic syndrome adhering to the C2 dermatome, a previously unreported distribution.

This article explores a rare skin condition called cryptococcoid Sweet syndrome, which can be triggered by infection, cancer, or certain medications. The case discussed involves a patient who had previously used hydralazine and had a history of cocaine use. The article emphasizes the connection between hydralazine use and autoimmune disorders like Sweet syndrome. It also stresses the importance of distinguishing between true cryptococcosis and cryptococcoid Sweet syndrome, and calls for more research on this condition and its potential causes. [Extracted from the article]

When prescribing low-dose methotrexate, frequent serological testing is recommended in the dermatologic literature, although much of the supporting data is extrapolated from non-dermatologic conditions. We performed a retrospective cohort study to determine the cumulative incidence and timing of low-dose methotrexate-associated serological abnormalities over the first year of therapy, in a pragmatic cohort of patients with dermatologic compared to non-dermatologic diagnoses. Laboratory values recorded included white blood cell count, hemoglobin, platelet count, estimated glomerular filtration rate, alanine aminotransferase, and aspartate aminotransferase. Among 1376 patients, there were no cases of methotrexate-associated grade 4/very severe lab abnormality or fatality. Baseline risk factors associated with moderate-to-severe lab abnormalities included non-dermatologic diagnoses, low hemoglobin, low estimated glomerular filtration rate, and elevated transaminases. The incidence of moderate-to-severe lab abnormalities was 4.4% among all patients, 3.1% among patients with dermatologic diagnoses, and 2.3% among patients with normal baseline lab values. Lab abnormalities led to discontinuation of therapy in 0.8% of patients. Serious changes did not occur in the first two weeks of therapy. We conclude that the cumulative incidence of low-dose methotrexate-associated lab abnormality was lower in patients with dermatologic diagnoses or normal baseline testing and these factors may be used to adjust monitoring practices. [ABSTRACT FROM AUTHOR]

Five years after receiving her diagnoses of psoriasis and palmoplantar pustulosis, the patient developed psoriatic arthritis with enthesitis. With the advent of targeted pharmacological therapies, patients and physicians have found new hope for conditions previously recalcitrant to conventional therapies. We propose tofacitinib as a therapy for treatment-refractory patients. [Extracted from the article]

Competing Interests: M.M.C. holds a copyright for the Skindex Mini. The remaining authors have no conflicts of interest to declare.